Filing Flows › Gossamer Bio (GOSS) › Q2 2026
Gossamer Bio (GOSS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Gossamer Bio (GOSS) reported revenue of $9.2M for the second quarter 2026 (Q2 2026), -20% from a year earlier and -46% from the quarter before. Operating margin was -282.2%, net earnings $16.9M (182.9% of revenue).
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | -46% | -20% |
| Operating profit | −$26.1M | — | — |
| Net earnings | $16.9M | — | — |
| Operating cash flow | −$39.4M | — | — |
What changed
Revenue was $9.2M in Q2 2026, down 20% year over year and down 46% from the previous quarter.
Operating costs exceeded revenue by $26.1M, an operating margin of -282.2%. Total costs fell 30% while revenue fell 20%. Net earnings were $16.9M. The effective tax rate was 0.0%. Non-operating items added $43.0M, 254% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$39.4M. Non-cash charges added back $2.5M of share-based compensation. Working capital and other items used $58.8M.
Questions
What was Gossamer Bio's revenue in the second quarter 2026?
Gossamer Bio (GOSS) reported revenue of $9.2M for the second quarter 2026 (Q2 2026), -20% from a year earlier and -46% from the quarter before.
Was Gossamer Bio profitable in the second quarter 2026?
Operating loss was $26.1M (-282.2% of revenue) and net earnings $16.9M.
Source: Gossamer Bio 10-Q on SEC EDGAR.